Abstract
Disease syndromes caused by Salmonella species continue to be important, as evidenced by a major outbreak of infection due to multiresistant Salmonella typhimurium in 1985; this outbreak involved more than 12,000 people in five north-central states of the United States. Salmonella species have become progressively more resistant in recent years to the clinically useful antibiotics (trimethoprim-sulfamethoxazole, ampicillin, and chloramphenicol). The clinical experience accumulated thus far indicates that two new classes of antimicrobial agents, the third-generation cephalosporins and the quinolones, offer significant potential for the treatment of specific problems in salmonellosis: bacteremia and enteric fever, meningitis, osteomyelitis, and the chronic carrier state.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Ampicillin / therapeutic use
-
Anti-Bacterial Agents / therapeutic use*
-
Carrier State / drug therapy
-
Cephalosporins / therapeutic use*
-
Chloramphenicol / therapeutic use
-
Cholecystectomy
-
Chronic Disease
-
Clinical Trials as Topic
-
Drug Combinations / therapeutic use
-
Humans
-
Meningitis / drug therapy
-
Microbial Sensitivity Tests
-
Osteomyelitis / drug therapy
-
Penicillin Resistance
-
Quinolines / therapeutic use*
-
Salmonella Infections / drug therapy*
-
Sepsis / drug therapy
-
Sulfamethoxazole / therapeutic use
-
Trimethoprim / therapeutic use
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Typhoid Fever / drug therapy
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
Drug Combinations
-
Quinolines
-
Chloramphenicol
-
Ampicillin
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Trimethoprim
-
Sulfamethoxazole